Comparison of cardiovascular risk assessment tools and their guidelines in evaluation of 10-year CVD risk and preventive recommendations: A population based study
- PMID: 27863362
- DOI: 10.1016/j.ijcard.2016.11.048
Comparison of cardiovascular risk assessment tools and their guidelines in evaluation of 10-year CVD risk and preventive recommendations: A population based study
Abstract
Background: Identification of individuals at risk of cardiovascular diseases (CVDs) results in better clinical outcomes and may help policy makers in conscious decision making for community based and national intervention strategies. The main aim of this study was to compare various CVD risk assessment tools and their related guidelines in estimation of 10-year CVD risk and subsequent therapeutic recommendations, respectively.
Methods: Data of 3086 subjects aged 40-74years from a cohort study of northern Iran were utilized in this cross-sectional study. The risks were calculated based on American College of Cardiology/American Heart Association (ACC/AHA) tool, two versions of Systematic Coronary Risk Evaluation (SCORE) equations (for low and high risk European countries) and Framingham approach. We also detected participants who ought to be recommended for treatment based on the specific guidelines related to each of the risk assessment tools.
Results: Mean cardiovascular risks were 12.96%, 8.84%, 1.90% and 3.45% in men and 5.87%, 2.13%, 0.8% and 1.13% in women based on ACC/AHA, Framingham, SCORE equation for low-risk European countries and high-risk European countries, respectively. Based on ACC/AHA, Adult Treatment Panel III (ATPIII) and European Society of Cardiology (ESC) guidelines related to SCORE equations for low and high risk European countries 58.2%, 27.1%, 21.1% and 28.6% of men and 39.7%, 33.0%, 29.5% and 30.7% of women were recommended to statin therapy, respectively.
Conclusions: In conclusion, more individuals were recommended for treatment by ACC/AHA guideline than the other guidelines.
Keywords: 10-Year cardiovascular risk; ACC/AHA guidelines; Cardiovascular diseases; Cardiovascular risk assessment tools; Framingham guidelines; SCORE risk charts.
Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.
Comment in
-
Cardiovascular risk assessment tools in non-Western populations.Int J Cardiol. 2018 Dec 1;272:331-332. doi: 10.1016/j.ijcard.2018.08.030. Epub 2018 Aug 13. Int J Cardiol. 2018. PMID: 30115420 No abstract available.
-
Further insight into 10-year CVD risk evaluation and recommended eligibility for statin therapy in Chinese population: Comparison of cardiovascular risk prediction models and their guidelines.Int J Cardiol. 2018 Nov 15;271:343. doi: 10.1016/j.ijcard.2018.04.010. Int J Cardiol. 2018. PMID: 30223366 No abstract available.
Similar articles
-
Comparison of application of the ACC/AHA guidelines, Adult Treatment Panel III guidelines, and European Society of Cardiology guidelines for cardiovascular disease prevention in a European cohort.JAMA. 2014 Apr 9;311(14):1416-23. doi: 10.1001/jama.2014.2632. JAMA. 2014. PMID: 24681960
-
Comparison of ACC/AHA and ESC Guideline Recommendations Following Trial Evidence for Statin Use in Primary Prevention of Cardiovascular Disease: Results From the Population-Based Rotterdam Study.JAMA Cardiol. 2016 Sep 1;1(6):708-13. doi: 10.1001/jamacardio.2016.1577. JAMA Cardiol. 2016. PMID: 27439175
-
CAC Score Improves Coronary and CV Risk Assessment Above Statin Indication by ESC and AHA/ACC Primary Prevention Guidelines.JACC Cardiovasc Imaging. 2017 Feb;10(2):143-153. doi: 10.1016/j.jcmg.2016.03.022. Epub 2016 Sep 21. JACC Cardiovasc Imaging. 2017. PMID: 27665163
-
The new pooled cohort equations risk calculator.Can J Cardiol. 2015 May;31(5):613-9. doi: 10.1016/j.cjca.2015.02.001. Epub 2015 Feb 4. Can J Cardiol. 2015. PMID: 25843167 Review.
-
What's next for dyslipidemia management? The 2013 ACC/AHA Guidelines, the NLA recommendations, and beyond.J Am Pharm Assoc (2003). 2016 May-Jun;56(3):284-92. doi: 10.1016/j.japh.2015.12.017. J Am Pharm Assoc (2003). 2016. PMID: 27156942 Review.
Cited by
-
Mediating effects of lower extremity function on the relationship between night sleep duration and cardiovascular disease risk: a cross-sectional study in elderly Chinese without cardiovascular diseases.BMJ Open. 2021 Jul 8;11(7):e046015. doi: 10.1136/bmjopen-2020-046015. BMJ Open. 2021. PMID: 34244261 Free PMC article.
-
Agreement between cardiovascular disease risk assessment tools: An application to the United Arab Emirates population.PLoS One. 2020 Jan 24;15(1):e0228031. doi: 10.1371/journal.pone.0228031. eCollection 2020. PLoS One. 2020. PMID: 31978187 Free PMC article.
-
Comparison of Framingham Cardiovascular Risk Criteria and ASCVD Score in Iranian Obese Patients.Iran J Public Health. 2023 Feb;52(2):420-426. doi: 10.18502/ijph.v52i2.11895. Iran J Public Health. 2023. PMID: 37089142 Free PMC article.
-
Estimation of the 10-Year Risk of Cardiovascular Diseases: Using the SCORE, WHO/ISH, and Framingham Models in the Shahrekord Cohort Study in Southwestern Iran.J Tehran Heart Cent. 2020 Jul;15(3):105-112. doi: 10.18502/jthc.v15i3.4219. J Tehran Heart Cent. 2020. PMID: 33552205 Free PMC article.
-
Comparing six cardiovascular risk prediction models in Haiti: implications for identifying high-risk individuals for primary prevention.BMC Public Health. 2022 Mar 19;22(1):549. doi: 10.1186/s12889-022-12963-x. BMC Public Health. 2022. PMID: 35305599 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
